Company news
Lumos Diagnostics Holdings Ltd. (ASX:LDX) news
Every Lumos Diagnostics Holdings Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
FY26 Full Year Results Announcement
August 25, 2026
Lumos Receives FebriDx Order from PHASE Scientific
August 3, 2026
FebriDx Commercial Traction Across Priority US Accounts
July 20, 2026
FebriDx U.S. Rollout and Reimbursement Update - Amended
May 18, 2026
FebriDx U.S. Rollout and Reimbursement Update
May 17, 2026
FebriDx Paediatric Study Enrolment Milestone Achieved
May 13, 2026
Response to ASX Aware Letter
April 10, 2026
Prospectus
April 9, 2026
Lumos secures new contract manufacturing agreement
April 8, 2026
Lumos receives largest FebriDx order to date
April 1, 2026
Investor Presentation
March 26, 2026
Lumos completes $20m placement and launches SPP
March 26, 2026
US FDA Grants CLIA Waiver for FebriDx
March 26, 2026
Trading Halt
March 24, 2026
Lumos Delivers Several Pivotal Milestones in 1H FY26
February 26, 2026
Appendix 4D and Half Year Report
February 26, 2026
Lumos Completes Enrolment Milestone for Paediatric Study
February 22, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Lumos Secures 100% US Medicare Reimbursement for FebriDx
November 21, 2025
Lumos secures follow-on PKU contract with Aptatek
August 31, 2025
LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
August 31, 2025
FY25 Appendix 4E
August 27, 2025
Lumos Announces FebriDx CLIA Waiver Application Submission
August 17, 2025
Lumos Signs Binding Term Sheet for A$5M Loan Facility
July 17, 2025
Lumos Signs Pivotal US FebriDx Agreement
July 16, 2025
Reinstatement to Quotation
July 16, 2025
Suspension from Quotation
July 14, 2025
Pause in Trading
July 11, 2025
Lumos Reaches FebriDx CLIA Waiver Study Enrolment Milestone
June 18, 2025
Lumos Reaches Recruitment Milestone in FebriDx Study
June 1, 2025
Lumos Secures Sixth US Medicare Reimbursement for FebriDx
May 26, 2025
Lumos Secures Fifth US Medicare Reimbursement for FebriDx
May 19, 2025
Lumos Advances FebriDx Sales with iMedical Purchase Order
May 13, 2025
Lumos Secures Further US Medicare Reimbursement for FebriDx
April 23, 2025
Lumos Secures Key US Reimbursement Milestones for FebriDx
April 17, 2025
Hologic Development Agreement Expanded Scope of Works
March 2, 2025
Commencement of FebriDx CLIA Waiver Study
December 19, 2024
Lumos receives CPT PLA Code for FebriDX in the US
December 4, 2024
Lumos Successfully Completes Retail Entitlement Offer
October 7, 2024
Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study
October 2, 2024
Lumos Awarded National Contract with MediGroup for FebriDx
September 25, 2024
Lumos Achieves First Phase 2 Milestone in Hologic Agreement
September 20, 2024
Lumos Appoints Thermo Fisher Scientific as US Distributor
September 15, 2024
Retail Entitlement Offer Booklet
September 10, 2024
Lumos Successfully Completes Institutional Entitlement Offer
September 5, 2024
Lumos Announces $10m Equity Raising and Welcomes Tenmile
September 4, 2024
Lumos Announces Intention to Undertake Entitlement Offer
September 3, 2024
FY24 Full Year Results Announcement
August 26, 2024
FY24 Appendix 4E
August 26, 2024
Lumos and BDI Progress New Point of Care Test
August 25, 2024